Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T86679 | Target Info | |||
Target Name | Adenosine A2b receptor (ADORA2B) | ||||
Synonyms |
Adenosine receptor A2b; A2b Adenosine receptor
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | ADORA2B | ||||
Biochemical Class | GPCR rhodopsin | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Adenosine A2a receptor (ADORA2A) | Successful Target | ||||
UniProt ID | AA2AR_HUMAN | |||||
Gene Name | ADORA2A | |||||
Synonyms |
Adenosine receptor A2a; ADORA2; A2a Adenosine receptor; A(2A) adenosine receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | KF-17837 | Drug Info | IC50 = 1 nM | Click to Show More | [1] | |
2 | Adenosine | Drug Info | Ki = 20 nM | [5] | ||
3 | YT-146 | Drug Info | Ki = 31.8 nM | [6] | ||
Co-Target Name | Adenosine A1 receptor (ADORA1) | Successful Target | ||||
UniProt ID | AA1R_HUMAN | |||||
Gene Name | ADORA1 | |||||
Synonyms |
Adenosine receptor A1; A(1) adenosine receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | Adenosine | Drug Info | IC50 = 2.344 nM | Click to Show More | [2] | |
2 | Tonapofylline | Drug Info | Ki = 7 nM | [3] | ||
3 | Tonapofylline | Drug Info | Ki = 7.4 nM | [4] | ||
Co-Target Name | Dipeptidyl peptidase 4 (DPP-4) | Successful Target | ||||
UniProt ID | DPP4_HUMAN | |||||
Gene Name | DPP4 | |||||
Synonyms |
Tcell activation antigen CD26; TP103; T-cell activation antigen CD26; Dipeptidyl peptidase IV; Dipeptidyl peptidase 4 soluble form; DPP-IV; DPP IV; DPP 4; CD26; Adenosine deaminase complexing protein-2; Adenosine deaminase complexing protein 2; ADCP2; ADCP-2; ADABP
Click to Show/Hide
|
|||||
Representative Drug(s) | Vidarabine | Drug Info | IC50 = 62 nM | [7] | ||
Co-Target Name | Adenosine A3 receptor (ADORA3) | Clinical trial Target | ||||
UniProt ID | AA3R_HUMAN | |||||
Gene Name | ADORA3 | |||||
Synonyms |
Adenosine receptor A3A; Adenosine receptor A3; Adenosine 3 receptor; A3AR; A3 Adenosine receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | Adenosine | Drug Info | IC50 = 1.148 nM | [2] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9. | ||||
REF 2 | Discovery of Novel Adenosine Receptor Agonists That Exhibit Subtype Selectivity. J Med Chem. 2016 Feb 11;59(3):947-64. | ||||
REF 3 | Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7132-9. | ||||
REF 4 | Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. | ||||
REF 5 | Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A?A adenosine receptor. J Med Chem. 2012 Jan 12;55(1):538-52. | ||||
REF 6 | Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. J Med Chem. 2016 Feb 11;59(3):788-809. | ||||
REF 7 | Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs. J Med Chem. 2010 Jan 28;53(2):559-72. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.